Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 20/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 20/20 | 0.67 |
| ▸ | S1PR3 | Q99500 | 20/20 | 0.67 |
| ▸ | LPAR2 | Q9HBW0 | 19/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979425 | 1.00 | S1PR2 (0.67) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15041925 | 0.89 | S1PR2 (0.55) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL1979555 | 0.89 | S1PR2 (0.52) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15023070 | 0.88 | S1PR2 (0.55) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15022717 | 0.87 | S1PR2 (0.55) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15022579 | 0.87 | S1PR2 (0.55) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15022929 | 0.86 | S1PR2 (0.53) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15022697 | 0.85 | S1PR2 (0.53) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15041932 | 0.85 | S1PR2 (0.57) | S1PR2S1PR1S1PR3LPAR2S1PR4 | |
| SCHEMBL15041926 | 0.85 | S1PR2 (0.57) | S1PR2S1PR1S1PR3LPAR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504323-B1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN INC (US) | 2017-03-15 | — | — | EP | claimed |
| US-20140107075-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-8440644-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2504323-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-10-03 | — | — | EP | claimed |
| US-20110212925-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-09-01 | — | — | US | claimed |
| WO-2011066184-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-06-03 | — | — | WO | claimed |
| EP-2504323-B1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741875-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741875-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140107075-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8440644-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2504323-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20110212925-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011066184-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107075-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885S1PR1 1/4885S1PR3 2/4885 |
| US-20110212925-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885S1PR1 1/4885S1PR3 2/4885 |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885S1PR1 1/4885S1PR3 2/4885 |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885S1PR1 1/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.